Evidence map›Paper›PMID 39558071›Full record

ArticleScientific reports2024

Digital PCR-based quantification of miR-181a in the cerebrospinal fluid aids patient stratification in pediatric acute lymphoblastic leukemia.

Borbála Péterffy, Tamás J Nádasi, Szilvia Krizsán, Anna Horváth, Ágnes Márk, Gábor Barna, Botond Timár, Laura Almási, Judit Müller, Krisztina Csanádi and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Borbála PéterffyHCEMM-SE, MTA-SE "Lendület" Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 26 Üllői Str, 1085, Budapest, Hungary.
Tamás J NádasiPediatric Center, Semmelweis University, 7-9 Tűzoltó Str, 1094, Budapest, Hungary.
Szilvia KrizsánHCEMM-SE, MTA-SE "Lendület" Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 26 Üllői Str, 1085, Budapest, Hungary.
Anna HorváthDepartment of Pathology and Experimental Cancer Research, Semmelweis University, 26 Üllői Str, 1085, Budapest, Hungary.
Ágnes MárkDepartment of Pathology and Experimental Cancer Research, Semmelweis University, 26 Üllői Str, 1085, Budapest, Hungary.
Gábor BarnaDepartment of Pathology and Experimental Cancer Research, Semmelweis University, 26 Üllői Str, 1085, Budapest, Hungary.
Botond TimárHCEMM-SE, MTA-SE "Lendület" Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 26 Üllői Str, 1085, Budapest, Hungary.
Laura AlmásiPediatric Center, Semmelweis University, 7-9 Tűzoltó Str, 1094, Budapest, Hungary.
Judit MüllerPediatric Center, Semmelweis University, 7-9 Tűzoltó Str, 1094, Budapest, Hungary.
Krisztina CsanádiHemato-Oncology Unit, Heim Pál Children's Hospital, 86 Üllői Str, 1089, Budapest, Hungary.
Anna RakonczaiDepartment of Internal Medicine and Hematology, Semmelweis University, 46 Szentkirályi Str, 1088, Budapest, Hungary.
Zsolt NagyDepartment of Internal Medicine and Hematology, Semmelweis University, 46 Szentkirályi Str, 1088, Budapest, Hungary.
Krisztián KállayDepartment of Pediatric Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, 5-7 Albert Flórián Str, 1097, Budapest, Hungary.
Gabriella KertészDepartment of Pediatric Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, 5-7 Albert Flórián Str, 1097, Budapest, Hungary.
Gergely KrivánDepartment of Pediatric Hematology and Stem Cell Transplantation, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, 5-7 Albert Flórián Str, 1097, Budapest, Hungary.
Monika CsókaPediatric Center, Semmelweis University, 7-9 Tűzoltó Str, 1094, Budapest, Hungary.
Anna SebestyénDepartment of Pathology and Experimental Cancer Research, Semmelweis University, 26 Üllői Str, 1085, Budapest, Hungary.
Ágnes F SemseiDepartment of Genetics, Cell- and Immunobiology, Semmelweis University, 4 Nagyvárad Square, 1089, Budapest, Hungary.
Gábor T KovácsPediatric Center, Semmelweis University, 7-9 Tűzoltó Str, 1094, Budapest, Hungary.
Dániel J ErdélyiPediatric Center, Semmelweis University, 7-9 Tűzoltó Str, 1094, Budapest, Hungary.
Csaba BödörHCEMM-SE, MTA-SE "Lendület" Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 26 Üllői Str, 1085, Budapest, Hungary.
Bálint Egyed *HCEMM-SE, MTA-SE "Lendület" Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 26 Üllői Str, 1085, Budapest, Hungary. egyed.balint@semmelweis.hu.
Donát Alpár *HCEMM-SE, MTA-SE "Lendület" Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 26 Üllői Str, 1085, Budapest, Hungary.

Funding

Complementary Research Excellence Program of Semmelweis University EFOP-3.6.3-VEKOP-16-2017-00009Horizon 2020 Framework Programme 739593Hungarian National Research, Development and Innovation Office PD145889, FK134253, K137948, K139139János Bolyai Research Scholarship BO/00125/22National Research, Development and Innovation Fund TKP2021-EGA-24, TKP2021-NVA-15Semmelweis Scientific and Innovation fund STIA-KFI-2022
6 · The paper itself

Abstract

Despite remarkable improvements in the survival of pediatric acute lymphoblastic leukemia (ALL), sensitive detection and clinical management of central nervous system leukemia (CNSL) are still immensely challenging. Blast cells residing in the CNS but not circulating in the cerebrospinal fluid (CSF) remain undetected by current diagnostic methods, preventing a truly risk-adapted anti-leukemic treatment in this compartment. We examined the clinical applicability of the molecular marker microRNA (miR)-181a quantified in the cell-free CSF to evaluate the level of CNS involvement and to optimize patient stratification based on CNS status. Normalized copy number of miR-181a was longitudinally profiled using droplet digital PCR, and the results were compared with the degree of leukemic involvement of the CNS. After combining cytospin- and flow cytometry (FCM) data with miR-181a expression, we could stratify previously ambiguous cases and reclassify patients into a CNS-positive/miR-significant group (mean ± SE for miR-181a copies: 3300.70 ± 809.69) bearing remarkable infiltration as well as into CNS-minimal/miR-significant and CNS-minimal/miR-minimal groups differentiating putative, clinically significant occult CNSL cases (2503.50 ± 275.89 and 744.02 ± 86.81 copies, respectively, p = 1.13 × 10

Indexed as

MicroRNAsPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentBiomarkers, TumorCentral Nervous System NeoplasmsChildChild, PreschoolFemaleFlow CytometryHumansInfantMalePolymerase Chain ReactionBiomarkers, TumorMicroRNAsMIrn181 microRNA, humanCerebrospinal fluidChildhood acute lymphoblastic leukemiaDiagnosticsMicroRNAMolecular genetics

Identifiers

PMID39558071
PMCPMC11574027

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.